OBJECTIVES: To estimated the budget impacts of immunization against pneumococcal disease (PD) and human papillomavirus (HPV), and of prophylaxis against severe respiratory syncytial virus (RSV) disease, in Israel. METHODS: Incidence-based models compared the annual budget impact, from the Israeli healthcare system perspective, of the PD and RSV programs.  Because HPV disease is slow developing, cumulative five-year disease costs were instead modelled for this program.  Model inputs were from published literature. Outputs included total program cost, disease costs and disease cost offsets, in 2012 Israeli New Shekels (NIS). RESULTS: A 13-valent pneumococcal conjugate vaccine (PCV13) vaccination program, covering 175,428 infants, prevented approximately 78 cases of invasive disease, 218 of pneumococcal pneumonia and 225 of pneumococcal otitis media. Immunization against HPV in a year’s cohort of 66,185 twelve-year old girls prevented approximately 321 cases of cervical intraepithelial neoplasia and 48 cases of genital warts over five years. RSV prophylaxis in 2,266 high-risk infants prevented approximately 138 hospitalizations for severe RSV disease.  Total disease costs in year one of the model, without the programs, were 7,250,461 NIS (PD) and 17,988,932 (RSV infection); cumulative five-year disease costs in the HPV model without immunization were 1,331,194 NIS. Total disease costs, with the programs (excluding the cost of prophylaxis) were 3,305,522 NIS (PD) and 14,426,876 NIS (RSV disease), for annual savings of 3,944,939 NIS and 3,562,056 NIS, respectively. HPV disease costs over five years with the program were 535,480 NIS, saving an estimated 795,713 NIS over five years. The immunization programs cost: 133,135,790 NIS (PD), 35,106,399 NIS (HPV) and 34,888,624 NIS (RSV disease).     CONCLUSIONS: All programs had substantial acquisition costs, but annual net savings, when the costs of the program were excluded.  Even programs considered expensive are well-positioned financially within the context of other childhood preventive health strategies, when targeted to appropriate populations.